239 related articles for article (PubMed ID: 32852602)
1. Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.
Yuan S; Xia Y; Shen L; Ye L; Li L; Chen L; Xie X; Lou H; Zhang J
Cancer Immunol Immunother; 2021 Feb; 70(2):533-546. PubMed ID: 32852602
[TBL] [Abstract][Full Text] [Related]
2. Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets.
Liu A; Zhang G; Yang Y; Xia Y; Li W; Liu Y; Cui Q; Wang D; Yu J
Cancer Immunol Immunother; 2024 Jun; 73(8):152. PubMed ID: 38833153
[TBL] [Abstract][Full Text] [Related]
3. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
[TBL] [Abstract][Full Text] [Related]
4. Prognostic nomogram based on pre-treatment HALP score for patients with advanced non-small cell lung cancer.
Gao S; Huang Q; Wei S; Lv Y; Xie Y; Hao Y
Clinics (Sao Paulo); 2024; 79():100371. PubMed ID: 38735175
[TBL] [Abstract][Full Text] [Related]
5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
6. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686
[TBL] [Abstract][Full Text] [Related]
7. A clinical nomogram based on absolute count of lymphocyte subsets for predicting overall survival in patients with non-small cell lung cancer.
Liu A; Zhang G; Yang Y; Xia Y; Li W; Liu Y; Cui Q; Wang D; Zhao J; Yu J
Int Immunopharmacol; 2023 Jan; 114():109391. PubMed ID: 36508919
[TBL] [Abstract][Full Text] [Related]
8. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
9. Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy.
Chang R; Qi S; Wu Y; Yue Y; Zhang X; Qian W
Cancer Imaging; 2023 Oct; 23(1):101. PubMed ID: 37867196
[TBL] [Abstract][Full Text] [Related]
10. A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab.
Shang X; Shi J; Wang X; Zhao C; Yu H; Wang H
Cancer Med; 2021 Sep; 10(18):6218-6226. PubMed ID: 34331414
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
12. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Novel Survival Prediction Model in Patients With Spinal Metastasis From Non-small Cell Lung Cancer.
Yang M; Xu W; Liu T; Yang X; Wang P; Wu S; Wei H; Zhao J; Yang C; Xiao J
Spine (Phila Pa 1976); 2019 Feb; 44(4):246-257. PubMed ID: 30059487
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Zeng H; Huang WW; Liu YJ; Huang Q; Zhao SM; Li YL; Tian PW; Li WM
Front Oncol; 2021; 11():685047. PubMed ID: 34458139
[TBL] [Abstract][Full Text] [Related]
15. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.
Suh KJ; Kim SH; Kim YJ; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
Cancer Immunol Immunother; 2018 Mar; 67(3):459-470. PubMed ID: 29204702
[TBL] [Abstract][Full Text] [Related]
16. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
PeerJ; 2022; 10():e14566. PubMed ID: 36540802
[TBL] [Abstract][Full Text] [Related]
17. Establishment and validation of a predictive nomogram model for non-small cell lung cancer patients with chronic hepatitis B viral infection.
Chen S; Lai Y; He Z; Li J; He X; Shen R; Ding Q; Chen H; Peng S; Liu W
J Transl Med; 2018 May; 16(1):116. PubMed ID: 29728103
[TBL] [Abstract][Full Text] [Related]
18. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
[TBL] [Abstract][Full Text] [Related]
19. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752
[TBL] [Abstract][Full Text] [Related]
20. Development, internal validation and calibration of a risk score to predict survival in patients with
Ng IK; Kumarakulasinghe NB; Syn NL; Soo RA
J Clin Pathol; 2021 Feb; 74(2):116-122. PubMed ID: 32576630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]